-
Mashup Score: 1
Health care companies are taking a step back to better understand patients’ experiences after a powerful U.S. health insurance executive was murdered last week, executives from drugmaker Pfizer and Amazon.com said at a panel at the Reuters NEXT conference in New York on Wednesday.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Candel's cancer therapy meets late-stage trial goal, shares soar - 4 hour(s) ago
Candel Therapeutics’ experimental immunotherapy for prostate cancer significantly improved the time patients lived before their disease returned, helping the company’s shares more than double in value in early trading.
Source: www.reuters.comCategories: General Medicine News, General NewsTweet-
Candel Therapeutics' experimental immunotherapy for prostate cancer significantly improved the time patients lived before their disease returned, helping the company's shares more than double in value in early trading. https://t.co/tO3du3ckqi https://t.co/tO3du3ckqi
-
-
Mashup Score: 0
AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly 40% lower.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet-
AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly 40% lower. https://t.co/2rmTlHvt1N https://t.co/2rmTlHvt1N
-
-
Mashup Score: 0
Former Nestle and Fresenius SE CEO Mark Schneider could succeed Jim Hagemann Snabe as chairman of the supervisory board of Siemens by 2027 at the latest, Siemens said on Wednesday, proposing Schneider’s election.
Source: www.reuters.comCategories: General Medicine News, General NewsTweet-
Former Nestle and Fresenius SE CEO Mark Schneider could succeed Jim Hagemann Snabe as chairman of the supervisory board of Siemens by 2027 at the latest, Siemens said on Wednesday, proposing Schneider's election. https://t.co/RiYOsekp2H https://t.co/RiYOsekp2H
-
-
Mashup Score: 2
Novel triple-drug therapies are showing promise for patients with various kinds of leukemia, researchers reported at the American Society of Hematology meeting in San Diego.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet-
Novel triple-drug therapies are showing promise for patients with various kinds of leukemia, researchers reported at the American Society of Hematology meeting in San Diego. https://t.co/ww9c9erEfb https://t.co/ww9c9erEfb
-
-
Mashup Score: 0
AnaptysBio said on Wednesday it would end the development of its eczema drug after it failed to meet the main and secondary goals of a mid-stage trial.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet-
AnaptysBio said on Wednesday it would end the development of its eczema drug after it failed to meet the main and secondary goals of a mid-stage trial. https://t.co/wVXVw45OMX https://t.co/wVXVw45OMX
-
-
Mashup Score: 2
There were around 11 million more cases of malaria in 2023 than in 2022, up to an estimated 263 million, according to a new World Health Organization report, marking another year of negligible progress against the age-old killer.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet-
There were around 11 million more cases of malaria in 2023 than in 2022, up to an estimated 263 million, according to a new World Health Organization report, marking another year of negligible progress against the age-old killer. https://t.co/pSpZYxuWRX https://t.co/pSpZYxuWRX
-
-
Mashup Score: 0Candel's cancer therapy meets late-stage trial goal, shares soar - 8 hour(s) ago
Candel Therapeutics’ experimental immunotherapy for prostate cancer significantly improved the time patients lived before their disease returned, helping the company’s shares more than double in value in early trading.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet-
Candel Therapeutics' experimental immunotherapy for prostate cancer significantly improved the time patients lived before their disease returned, helping the company's shares more than double in value in early trading. https://t.co/U16aHX1BRY https://t.co/U16aHX1BRY
-
-
Mashup Score: 0
AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly 40% lower.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet-
AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly 40% lower. https://t.co/4rX2opHsXJ https://t.co/4rX2opHsXJ
-
-
Mashup Score: 0
Former Nestle and Fresenius SE CEO Mark Schneider could succeed Jim Hagemann Snabe as chairman of the supervisory board of Siemens by 2027 at the latest, Siemens said on Wednesday, proposing Schneider’s election.
Source: www.reuters.comCategories: General Medicine News, General HCPsTweet-
Former Nestle and Fresenius SE CEO Mark Schneider could succeed Jim Hagemann Snabe as chairman of the supervisory board of Siemens by 2027 at the latest, Siemens said on Wednesday, proposing Schneider's election. https://t.co/13jIFPBQq3 https://t.co/13jIFPBQq3
-
Health execs reckon with patient outrage after UnitedHealthcare killing https://t.co/Fbt3fLcu4o https://t.co/Fbt3fLcu4o